Cancer Research Communications

Scope & Guideline

Elevating cancer research to new heights.

Introduction

Immerse yourself in the scholarly insights of Cancer Research Communications with our comprehensive guidelines detailing its aims and scope. This page is your resource for understanding the journal's thematic priorities. Stay abreast of trending topics currently drawing significant attention and explore declining topics for a full picture of evolving interests. Our selection of highly cited topics and recent high-impact papers is curated within these guidelines to enhance your research impact.
LanguageEnglish
ISSN-
PublisherAMER ASSOC CANCER RESEARCH
Support Open AccessNo
Country-
Type-
Converge-
AbbreviationCANCER RES COMMUN / Cancer Res. Commun.
Frequency1 issue/year
Time To First Decision-
Time To Acceptance-
Acceptance Rate-
Home Page-
Address615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404

Aims and Scopes

Cancer Research Communications aims to advance knowledge in the field of oncology through cutting-edge research and clinical studies. The journal encompasses a wide array of topics related to cancer biology, therapy, and patient outcomes, focusing on innovative approaches and methodologies.
  1. Cancer Therapeutics and Targeted Treatments:
    The journal regularly publishes studies on novel therapeutic agents, including targeted therapies, immunotherapies, and combination treatments. This includes exploration of drug mechanisms, resistance, and patient stratification based on genetic and molecular profiles.
  2. Cancer Biology and Mechanisms of Tumorigenesis:
    Research articles delve into the fundamental biological processes underlying cancer development and progression. This includes studies on genetic mutations, signaling pathways, and tumor microenvironment interactions that contribute to malignancy.
  3. Clinical Trials and Translational Research:
    A significant focus is placed on clinical studies, including phase I-III trials, that evaluate the safety and efficacy of new cancer treatments. This also includes studies on biomarkers and patient outcomes to inform clinical decision-making.
  4. Molecular and Cellular Oncology:
    The journal features research on cellular mechanisms, including the role of cancer stem cells, immune evasion, and the tumor microenvironment, emphasizing the molecular pathways that contribute to cancer progression.
  5. Cancer Epidemiology and Health Disparities:
    Research addressing disparities in cancer incidence, treatment outcomes, and access to care for various populations is a consistent theme. This includes studies that investigate the impact of socioeconomic factors on cancer risk and treatment.
Recent publications in Cancer Research Communications highlight several trending and emerging themes that demonstrate the journal's responsiveness to the evolving landscape of cancer research. These themes indicate where the field is heading and the innovative approaches being taken.
  1. Immunotherapy and Immune Microenvironment Studies:
    There is a significant increase in research focused on immunotherapy, including CAR T-cell therapies and immune checkpoint inhibitors. Studies exploring the immune microenvironment and its role in therapy response are gaining prominence, reflecting the growing importance of immuno-oncology.
  2. Precision Medicine and Biomarker Research:
    Publications increasingly emphasize the role of precision medicine, with a focus on identifying biomarkers for patient stratification and treatment efficacy. This trend aligns with the need for personalized treatment approaches tailored to individual patient profiles.
  3. Multi-Omics Approaches:
    Emerging research utilizing multi-omics strategies, such as genomics, proteomics, and metabolomics, is becoming more prevalent. These approaches aim to provide a comprehensive understanding of cancer biology and treatment responses.
  4. Targeting the Tumor Microenvironment:
    Studies investigating the tumor microenvironment's role in cancer progression and therapy resistance are on the rise. This includes research on stromal interactions, immune cell infiltration, and metabolic reprogramming within tumors.
  5. Health Disparities and Cancer Epidemiology:
    There is a growing focus on understanding health disparities in cancer outcomes, with research highlighting the influence of socioeconomic, racial, and geographic factors on cancer incidence and treatment access. This trend reflects a broader commitment to addressing inequities in cancer care.

Declining or Waning

While Cancer Research Communications continues to explore a vast array of cancer-related topics, certain themes appear to be declining in frequency or prominence. These waning scopes may reflect shifts in research focus or emerging priorities in the field.
  1. Traditional Chemotherapy Studies:
    There has been a noticeable decrease in studies focused solely on traditional chemotherapy regimens, as research increasingly shifts towards personalized medicine and targeted therapies that offer improved specificity and reduced toxicity.
  2. Basic Laboratory Techniques without Clinical Relevance:
    Research papers that focus exclusively on basic laboratory techniques or models, without a clear translational application or clinical relevance, appear to be less frequently published, as the journal emphasizes studies with direct implications for patient care.
  3. Single-Factor Studies:
    There is a waning interest in studies that investigate single factors in isolation, such as individual genetic mutations or isolated biochemical pathways, as the field moves towards integrative approaches that consider the multifactorial nature of cancer.
  4. General Cancer Awareness Campaigns:
    Papers focused on general cancer awareness and education initiatives without substantial data or research backing are becoming less prevalent, reflecting a trend towards more evidence-based, impactful research.

Similar Journals

CANCER SCIENCE

Exploring the forefront of cancer science and medicine.
Publisher: WILEYISSN: 1347-9032Frequency: 12 issues/year

Cancer Science, an esteemed journal published by Wiley, stands at the forefront of oncology research, boasting an impressive impact factor and a classification in the Q1 category for its contributions in Cancer Research, Medicine, and Oncology as of 2023. Since its inception in 2003 and transitioning to an Open Access model in 2014, the journal has facilitated global dissemination of critical research findings, ensuring that vital information remains accessible to researchers, clinicians, and students alike. With its comprehensive scope covering cutting-edge discoveries in cancer biochemistry, genetics, and molecular biology, Cancer Science is recognized for its rigorous peer-review process and significant contributions to advancing our understanding of cancer. The journal, located at 111 River St, Hoboken, NJ, is an essential resource for anyone dedicated to improving treatment outcomes and pushing the boundaries of cancer research.

NATURE REVIEWS CANCER

Elevating Cancer Research with Comprehensive Reviews
Publisher: NATURE PORTFOLIOISSN: 1474-175XFrequency: 12 issues/year

NATURE REVIEWS CANCER, a premier journal published by NATURE PORTFOLIO, stands as a cornerstone in the field of oncology, focusing on delivering high-quality, comprehensive reviews that shape our understanding of cancer biology, prevention, and treatment. With an impressive impact in the academic community, it ranks Q1 in both Cancer Research and Oncology categories as of 2023, further denoted by a remarkable Scopus ranking as the top journal in Cancer Research and second in Oncology. This ensures that published articles not only set the standard for scientific excellence but also drive significant advancements in cancer research methodologies and practices. The journal's targeted audience, including researchers, practitioners, and students, will greatly benefit from its insightful analyses and interdisciplinary approach. While it operates under a traditional subscription model, the rich content and vast expertise presented in its articles foster a global dialogue on cancer-related issues, making it an essential resource for anyone dedicated to the advancement of cancer science.

CANCER BIOLOGY & THERAPY

Leading the charge in cancer research and patient care.
Publisher: TAYLOR & FRANCIS INCISSN: 1538-4047Frequency: 12 issues/year

CANCER BIOLOGY & THERAPY is a premier open-access journal published by Taylor & Francis Inc, dedicated to advancing the field of cancer research and treatment. Since its inception in 2002, the journal has evolved to provide a platform for innovative research and groundbreaking findings, addressing critical aspects of cancer biology, pharmacology, and molecular medicine. With an impressive impact factor and recognition as a Q2 journal in vital categories such as Cancer Research, Oncology, and Pharmacology, it holds significant standing in Scopus rankings, reflecting its influence and commitment to disseminating high-quality research. Offering researchers, professionals, and students a wealth of knowledge, CANCER BIOLOGY & THERAPY stands at the forefront of the fight against cancer, presenting the latest developments and therapeutic strategies vital for improving patient outcomes. Accessible to all since 2022, this journal is a must-read for anyone involved in the multifaceted arena of cancer research and treatment.

CANCER INVESTIGATION

Pioneering insights in oncology for a healthier tomorrow.
Publisher: TAYLOR & FRANCIS INCISSN: 0735-7907Frequency: 10 issues/year

CANCER INVESTIGATION is a distinguished peer-reviewed journal published by Taylor & Francis Inc, dedicated to the advancing field of cancer research and oncology. With an ISSN of 0735-7907 and E-ISSN of 1532-4192, this journal has been a pivotal resource for professionals and researchers since its inception in 1983, continually contributing to the evolving landscape of cancer investigation until its convergence in 2024. CANCER INVESTIGATION boasts noteworthy rankings in 2023, including Q3 in Cancer Research and Q2 in Medicine (miscellaneous), highlighting its relevance and impact in these critical areas. The journal's commitment to disseminating innovative research and comprehensive reviews makes it an essential platform for those engaged in cancer studies and related disciplines. While currently not available as an open-access publication, CANCER INVESTIGATION remains an invaluable tool for understanding the complexities of cancer, offering insights that drive scientific advancements and improve patient outcomes.

Annual Review of Cancer Biology

Transforming Insights into Cancer Biology
Publisher: ANNUAL REVIEWSISSN: 2472-3428Frequency: 1 issue/year

Annual Review of Cancer Biology is a pivotal journal published by Annual Reviews, specializing in the rapidly evolving field of cancer research. With an impact factor positioned in the distinguished Q1 quartile of Cancer Research, Cell Biology, and Oncology categories, this journal ensures that it showcases the highest quality of scholarly contributions. Indexed in Scopus, it ranks among the top in its fields, reflecting its strong influence and relevance, with remarkable percentiles indicating its esteemed position within the research community. Although not an open-access journal, it provides a comprehensive platform for advancing the frontiers of cancer biology through rigorously curated reviews, highlighting key developments, breakthroughs, and future directions that inform both academia and clinical applications. As a valuable resource for researchers, professionals, and students, the Annual Review of Cancer Biology serves as an essential guide for understanding and addressing the complexities of cancer biology today.

JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH

Empowering the global fight against cancer with open access.
Publisher: BMCISSN: Frequency: 1 issue/year

The JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH, published by BMC, is a leading open-access journal dedicated to advancing the field of cancer research and oncology. Since its inception in 1982, this esteemed journal has fostered innovation and collaboration in the scientific community, as evidenced by its outstanding impact factor and position in the Q1 quartile for both Cancer Research and Oncology categories in 2023. With a proud commitment to disseminating high-quality research, the journal operates under an open-access model, ensuring that findings are readily accessible to researchers, healthcare professionals, and students worldwide. The journal has established a distinguished reputation, ranking 23rd out of 404 in Medicine oncology and 16th out of 230 in Biochemistry, Genetics, and Molecular Biology (cancer research), showcasing its importance and influence in guiding the future of cancer treatment and research. With the aim of bridging experimental and clinical research, this journal invites submissions that push the boundaries of our understanding of cancer biology and therapy.

Cancer Drug Resistance

Innovating Solutions for Effective Cancer Therapy.
Publisher: OAE PUBLISHING INCISSN: Frequency: 1 issue/year

Cancer Drug Resistance is a premier journal published by OAE PUBLISHING INC, focusing on the critical field of oncology and pharmacology. Since its inception in 2018, the journal has been at the forefront of presenting innovative research aimed at understanding and overcoming drug resistance in cancer therapy. With an impressive impact factor reflected in its Q2 ranking in Cancer Research and a Q1 ranking in Pharmacology (medical) for 2023, Cancer Drug Resistance serves as a vital resource for researchers, clinicians, and students who are dedicated to advancing cancer treatment and improving patient outcomes. The journal's commitment to disseminating high-quality, peer-reviewed articles underscores its importance within the academic and medical communities. While it operates on an open-access model, facilitating widespread distribution and access to crucial research findings, the journal continuously strives to foster dialogue and collaboration among stakeholders in cancer research and pharmacology. Its mission is clear: to shine a light on the evolving challenges and breakthroughs in drug resistance, paving the way for enhanced therapeutic strategies and clinical solutions.

Cancers

Advancing cancer research for a healthier tomorrow.
Publisher: MDPIISSN: Frequency: 24 issues/year

Cancers is a leading peer-reviewed journal published by MDPI, dedicated to advancing the field of oncology and cancer research. Established in 2009 and based in Switzerland, this Open Access journal provides a platform for the rapid dissemination of high-quality research findings, reviews, and clinical studies related to all aspects of cancer biology and treatment. With an impressive impact factor and recognized as Q1 in Oncology and Q2 in Cancer Research for 2023, Cancers strives to foster a collaborative environment among researchers, healthcare professionals, and students seeking to deepen their knowledge and understanding of cancer. The journal’s commitment to accessibility and its broad scope make it an invaluable resource for anyone passionate about combating cancer and improving patient outcomes. For more information and to access its diverse publications, visit the journal’s website.

Oncologie

Pioneering insights in the fight against cancer.
Publisher: WALTER DE GRUYTER GMBHISSN: 1292-3818Frequency: 6 issues/year

Oncologie is a distinguished academic journal published by WALTER DE GRUYTER GMBH, focusing on the dynamic and vital field of oncology. Established in 1999 and continuously published until 2024, this journal provides a platform for high-quality research and advancements in cancer treatment, prevention, and diagnosis. With an ISSN of 1292-3818 and an E-ISSN of 1765-2839, it is indexed in various databases, contributing to its growing visibility. Although categorized in the Q3 quartile for oncology research as of 2023, Oncologie offers essential insights and fosters scholarly dialogue among researchers, professionals, and students interested in oncology. Its unique contributions aim to bridge the gap between theoretical frameworks and clinical applications, making it a valuable resource for those seeking to advance their knowledge and expertise in cancer research.

CANCER

Driving innovation in cancer treatment and biology.
Publisher: WILEYISSN: 0008-543XFrequency: 24 issues/year

CANCER, published by Wiley, stands as a pivotal journal in the field of oncology and cancer research, boasting an impressive impact factor and consistently dynamic growth since its inception in 1948. With an ISSN of 0008-543X and an E-ISSN of 1097-0142, this esteemed journal is recognized for its rigorous peer-reviewed articles, making significant contributions to the understanding of cancer biology, treatment modalities, and clinical practices. CANCER holds a distinguished position in the academic community, securing its placement in the Q1 category for both cancer research and oncology, and ranks within the top percentiles on Scopus, indicating its high impact and relevance. The journal is particularly beneficial for researchers, professionals, and students seeking to stay abreast of the latest advancements in cancer science. By addressing essential research questions and providing pathways for new therapies, CANCER continues to play a crucial role in shaping the future of oncology and improving patient outcomes.